Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy
Erik J Groessl,Steven R Tally,Naomi Hillery
DOI: https://doi.org/10.2147/CEOR.S400739
2023-04-06
ClinicoEconomics and Outcomes Research
Abstract:Erik J Groessl, 1, 2 Steven R Tally, 1 Naomi Hillery 1 1 Health Services Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, CA, USA; 2 VA San Diego Healthcare System, San Diego, CA, USA Correspondence: Erik J Groessl, University of California San Diego, Health Services Research Center, 9500 Gilman Drive, Mail Code 0994, San Diego, CA, 92037, USA, Tel +1 858 622 1771, Email Purpose: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality, and is associated with significant respiratory impairment, decreased quality of life, and high health care costs. Recent evidence indicates significant clinical benefit results from adding humidified high-flow therapy (HHFT) to standard long-term oxygen therapy (LTOT) as a home-based therapy in persons with severe COPD. The objective was to evaluate the cost-effectiveness of adding HHFT to standard treatment of COPD patients using LTOT with US healthcare cost estimates. Patients and Methods: A Markov state-transition model was developed using data from a prospective clinical trial of adding HHFT to standard therapy for persons with severe COPD using LTOT. The analysis was conducted from the US health care system perspective using a 5-year time horizon and 3% discount rate. QALYs and downstream healthcare costs were modeled. One-way and probabilistic sensitivity analyses were used to examine the impact of input parameters on the incremental net monetary benefit (NMB). Results: Incremental QALYs accrued were 0.058 (2.047 vs 1.989 QALYs for HHFT and standard therapy groups respectively). Incremental total costs were -&dollar3939 (&dollar47,516 vs &dollar51,455 for HHFT and standard therapy groups respectively). Thus, HHFT was the dominant treatment in the analysis, resulting on both better health and lower total costs. Varying utility and cost inputs individually never resulted in NMB approaching 0. Probabilistic analyses indicate that HHFT is cost-effective in 84% of simulations. Conclusion: Our results indicate that the reductions in acute exacerbations of COPD (AECOPDs) that result from adding HHFT for persons with COPD on LTOT will produce both health benefit (QALYs) and cost savings. Cost savings occur because the HHFT device costs are more than offset by reductions in costly COPD exacerbations. Health care systems and payors can benefit from wider implementation of HHFT with existing treatments. Keywords: COPD, acute exacerbations, cost-effectiveness, humidified high flow therapy Chronic obstructive pulmonary disease (COPD) is now the third leading cause of death worldwide, estimated to account for 6% of all deaths according to the World Health Organization. 1 Patients with COPD experience persistent respiratory symptoms such as dyspnea, cough, and/or sputum production due to abnormalities within the airway or alveoli. 2 At the population level, COPD is associated with a decreased quality of life, decreased life expectancy, and higher healthcare costs. 2 In the US, healthcare costs for COPD were second only to asthma among respiratory conditions, with spending estimated at over $34 billion. 3 Furthermore, despite the large known impact on morbidity and mortality, it is estimated that COPD is underdiagnosed, as many cases are only identified during or after a severe episode. 4 COPD is a complex disease, influenced by a multitude of factors such as genetics, environment, comorbidities, and lifestyle risk factors. 5 Because of this heterogeneity, COPD can be difficult to treat, particularly in advanced stages of the disease. COPD identification and progression is often more easily characterized by symptoms and exacerbations. 5 Exacerbations are defined by The Global Initiative for Chronic Obstructive Lung Disease (GOLD) as episodes of "acute worsening of respiratory symptoms that result in additional therapy". 6 These episodes are categorized as either mild, moderate, or severe, depending on the requisite treatment to stabilize the patient. 6 Severe COPD exacerbations occur less frequently as compared with mild or moderate, but can be debilitating and life-threatening, thus requiring hospitalization. Well-established treatments for COPD include pharmacologic therapy such as inhaled steroids or long-acting bronchodilators and pulmonary rehabilitation. Patients with chronic and/or severe symptoms may require long-term oxygen therapy (LTOT) to address severe resting chronic hypoxemia. LTOT is an established therapy to prevent hypoxemia as recommended in numerous medical guidelines. 7,30 Patients started on LTOT are usuall -Abstract Truncated-